Global Health (MEDANTA) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
18 Jun, 2026Executive summary
Achieved record quarterly total income and EBITDA in Q1 FY2026, with 19% year-on-year topline growth driven by increased patient volumes and higher realization.
PAT grew 49.6% year-on-year, aided by a non-recurring exceptional income of INR 196 million from reversal of interest liability.
Onboarded over 150 doctors, including 30 senior clinicians, and expanded network with a new 110-bed hospital in Ranchi; Noida 550-bed facility to commence with 300 beds in Q2 FY26.
Board approved unaudited financial results for Q1 FY26, proposed a final dividend of Rs. 0.50 per share, and re-appointed key directors.
Merger of MHPL with GHL completed, with Lucknow unit now included in standalone results.
Financial highlights
Consolidated total income reached INR 10,513 million, up 19.1% year-on-year; EBITDA rose to INR 2,553 million, a 22.6% increase, with margins at 24.3%.
PAT was INR 1,590 million, up 49.6% year-on-year, with margins at 15.1%.
Inpatient volumes grew 14% and outpatient volumes 13% year-on-year; average occupied bed days up 13% with 63% occupancy.
Revenue from international patients increased 34% year-on-year to INR 636 million.
Standalone revenue from operations for Q1 FY26: ₹8,821.56 million; consolidated profit after tax: ₹1,589.82 million.
Outlook and guidance
Near-term goal to add 1,000 beds, with a pipeline of 2,000–3,000 beds over 3–5 years and total capex of ~INR 40,000 million.
Expansion projects underway in Noida, South Delhi, Mumbai, Pitampura, and Guwahati.
Conservative approach to tariff hikes, with selective increases possible in Gurugram, Lucknow, and Patna.
Employee long-term share-based incentive plan implemented.
Latest events from Global Health
- Double-digit growth in revenue and profit, with major expansions and strong patient volume momentum.MEDANTA
Q3 24/2518 Jun 2026 - Double-digit growth, major expansion, and a first-ever dividend marked a strong FY2025.MEDANTA
Q4 24/2518 Jun 2026 - Strong revenue and profit growth, network expansion, and disciplined capex marked FY26.MEDANTA
Q4 25/2620 May 2026 - Q3 FY26 saw 19% revenue growth, strong margins, and major expansion despite ramp-up costs.MEDANTA
Q3 25/2613 Apr 2026 - Q2 FY2026 delivered double-digit growth, major expansion, and strong cash flows.MEDANTA
Q2 25/2610 Nov 2025 - Q1 FY25 saw revenue and profit growth, with major expansion and strategic investments announced.MEDANTA
Q1 24/2527 Aug 2025 - Strong Q2 and H1 FY25 growth, new incentive plan, and expansion with a new hospital agreement.MEDANTA
Q2 24/2527 Aug 2025